The latest evaluation of molecular subgroups of gliomas identified ATRX, CIC, and FUBP1 mutations, and allowed distinguishing patients with IDH1/CIC/FUBP1 or IDH1/ATRX mutations [15]. This evidence concerns the gene CIC and central nervous system cancer.